Influence of the surface charge of PLGA nanoparticles on their in vitro genotoxicity, cytotoxicity, ROS production and endocytosis

Journal of Applied Toxicology

Volumn 36, Issue 3, 2016, Pages 434-444

  Platel, Anne ^a,b,c   Carpentier, Rodolphe ^d,e   Becart, Elodie ^a,b   Mordacq, Gwendoline ^a,b   Betbeder, Didier ^a,d,e   Nesslany, Fabrice ^a,b,c  

^a UNIV LILLE   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UFR3S Pharmacie   (France)

^d UNIVERSITÉ DE LILLE   (France)

^e UNIVERSITÉ D'ARTOIS   (France)

Author keywords

16HBE14o human bronchial epithelial cells; Endocytosis; Genotoxicity, cytotoxicity; L5178Y mouse lymphoma cells; Nanoparticles of PLGA; ROS; TK6 human lymphoblastoid cells

Indexed keywords

NANOPARTICLE; POLY(LACTIC CO GLYCOLIC ACID) NANOPARTICLE; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CLATHRIN; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANEUPLOIDY; ANIMAL CELL; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; EPITHELIUM CELL; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE CHARGE; SYNTHESIS; ANIMAL; BRONCHUS; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; COMET ASSAY; COMPARATIVE STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; LYMPHOMA; METABOLISM; MICRONUCLEUS; MICRONUCLEUS TEST; OXIDATIVE STRESS; PATHOLOGY; RISK ASSESSMENT; SURFACE PROPERTY; TUMOR CELL LINE;

ANEUPLOIDY; ANIMALS; BRONCHI; CELL LINE, TUMOR; CELL SURVIVAL; CLATHRIN; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; EPITHELIAL CELLS; HUMANS; LACTIC ACID; LYMPHOMA; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; NANOPARTICLES; OXIDATIVE STRESS; POLYGLYCOLIC ACID; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; SURFACE PROPERTIES;

EID: 84955646763     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3247     Document Type: Article

References (52)

1. Afssaps. 2011. Recommandations relatives à l'évaluation toxicologique des médicaments sous forme nanoparticulaire. http://ansm.sante.fr/var/ansm_site/storage/original/application/7042aee471537987a082180039a5bded.pdf [accessed 18 January 2014].
2. Bauer E, Recknagel RD, Fiedler U, Wollweber L, Bock C, Greulich KO. 1998. The distribution of the tail moments in single cell gel electrophoresis (comet assay) obeys a chi-square (chi2) not a gaussian distribution. Mutat. Res. 398: 101-110.
3. Bhattacharjee S, Ershov D, Gucht J, Alink GM, Rietjens IMCM, Zuilhof H, Marcelis ATM. 2013. Surface charge-specific cytotoxicity and cellular uptake of tri-block copolymer nanoparticles. Nanotoxicology 7: 71-84.
4. Borenfreund E, Babich H, Martin-Alguacil N. 1988. Comparison of two in vitro cytotoxicity assays: the neutral red (NR) and tetrazolium MTT tests. Toxicol. In Vitro 2: 1-6.
5. Chang J, Paillard A, Passirani C, Morille M, Benoit JP, Betbeder D, Garcion E. 2012. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. 29: 1495-1505.
6. Collins AR, Oscoz AA, Brunborg G, Gaivão I, Giovannelli L, Kruszewski M, Smith CC, Stetina R. 2008. The comet assay: topical issues. Mutagenesis 23: 143-151.
7. Collins AR, Duthie SJ, Dobson VL. 1993. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 14: 1733-1735.
8. Dombu CY, Kroubi M, Zibouche R, Matran R, Betbeder D. 2010. Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology 21: 355102.
9. Donaldson K, Poland CA, Schins RP. 2010. Possible genotoxic mechanisms of nanoparticles: Criteria for improved test strategies. Nanotoxicology 4: 414-420.
10. Fenech M. 2003. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat. Res. 534: 65-75.
11. Fenech M. 2000. The in vitro micronucleus technique. Mutat. Res. 455: 81-95.
12. Fenech M, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, Knasmüller S, Holland N. 2007. Harmonisation of the micronucleus assay in human buccal cells-a Human Micronucleus (HUMN) project (www.humn.org) initiative commencing in 2007. Mutagenesis 22: 3-4.
13. Fielding AB, Willox AK, Okeke E, Royle SJ. 2012. Clathrin-mediated endocytosis is inhibited during mitosis. Proc. Natl. Acad. Sci. U. S. A. 109: 6572-6577.
14. Foerg C, Ziegler U, Fernandez-Carneado J, Giralt E, Merkle HP. 2007. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharm. Res. 24: 628-642.
15. Fröhlich E, Meindl C, Robleg E, Griesbacher A, Pieber TR. 2012. Cytotoxity of nanoparticles is influenced by size, proliferation and embryonic origin of the cells used for testing. Nanotoxicology 6: 424-439.
16. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. 2008. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. U. S. A. 105: 11613-11618.
17. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. 2007. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353: 26-32.
18. Honma M. 2005. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells. Environ. Mol. Mutagen. 45: 162-176.
19. Honma M, Hayashi M. 2011. Comparison of in vitro micronucleus and gene mutation assay results for p53-competent versus p53-deficient human lymphoblastoid cells. Environ. Mol. Mutagen. 52: 373-384.
20. ISO. 2008. Nanotechnologies-Terminology and definitions for nano-objects-Nanoparticle, nanofibre and nanoplate. ISO/TS 27687: 2008.
21. Kirsch-Volders M, Vanhauwaert A, De Boeck M, Decordier I. 2002. Importance of detecting numerical versus structural chromosome aberrations. Mutat. Res. 504: 137-148.
22. Kroll A, Dierker C, Rommel C, Hahn D, Wohlleben W, Schulze-Isfort C, Göbbert C, Voetz M, Hardinghaus F, Schnekenburger J. 2011. Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays. Particle & Fibre 8: 2-19.
23. Kumari A, Yadav SK, Yadav SC. 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75: 1-18.
24. Le Broc-Ryckewaert D, Carpentier R, Lipka E, Daher S, Vaccher C, Betbeder D, Furman C. 2013. Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. Int. J. Pharm. 454: 712-719.
25. Lee KD, Nir S, Papahadjopoulos D. 1993. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32: 889-899.
26. Liber HL, Thilly WG. 1982. Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. Mutat. Res. 94: 467-485.
27. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. 2009. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 4: 325-341.
28. McNamee CE, Pyo N, Higashitani K. 2006. Atomic force microscopy study of the specific adhesion between a colloid particle and a living melanoma cell: Effect of the charge and the hydrophobicity of the particle surface. Biophys. J. 91: 1960-1969.
29. Magdolenova Z, Collins A, Kumar A, Dhawan A, Stone V, Dusinska M. 2014. Mechanisms of genotoxicity. A review of in vitro and in vivo studies with engineered nanoparticles. Nanotoxicology 8: 233-278.
30. Merhi M, Youta Dombu C, Brient A, Chang J, Platel A, Le Curieux F, Marzin D, Nesslany F, Betbeder D. 2012. Study of serum interaction with a cationic nanoparticle: implications for in vitro endocytosis, cytotoxicity and genotoxicity. Int. J. Pharm. 423: 37-44.
31. Miller BM, Pujadas E, Gocke E. 1995. Evaluation of the micronucleus test in vitro using Chinese hamster cells: results of four chemicals weakly positive in the in vivo micronucleus test. Environ. Mol. Mutagen. 26: 240-247.
32. Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, Klaessig F, Castranova V, Thompson M. 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8: 543-557.
33. Nemmar A, Hoylaerts MF, Hoet PH, Vermylen J, Nemery B. 2003. Size effect of intracellularly instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol. Appl. Pharmacol. 186: 38-45.
34. Nesslany F, Marzin D. 1999. A micromethod for the in vitro micronucleus assay. Mutagenesis 14: 403-410.
35. OECD. 2008. OECD Environment, Health and Safety Publications, Series on the Safety of Mnufactured Nanomaterials. No. 6, Working Party on Manufactured Nanomaterials: list of manufactured nanomaterials and list of endpoints for phase one of the OECD testing programme. ENV/JM/MONO(2008)13/REV.
36. OECD. 2014. Test No. In 487: In Vitro Mammalian Cell Micronucleus Test, OECD Guidelines for Testing of Chemicals, Section 4. OECD Publishing: Paris.
37. Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55: 329-347.
38. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. 2002. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16: 1217-1226.
39. Quintart J, Leroy-Houyet MA, Trouet A, Baudhuin P. 1979. Endocytosis and chloroquine accumulation during the cell cycle of hepatoma cells in culture. J. Cell Biol. 82: 644-653.
40. Singh N, Manshian B, Jenkins GJ, Griffiths SM, Williams PM, Maffeis TG, Wright CJ, Doak SH. 2009. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. Biomaterials 30: 3891-3914.
41. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175: 184-191.
42. Smith CC, O'Donovan MR, Martin EA. 2006. hOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII. Mutagenesis 21: 185-190.
43. Ruizendaal L, Bhattacharjee S, Pournazari K, Rosso-Vasic M, de Haan LHJ, Alink GM, Marcelis ATM. 2009. Synthesis and cytotoxicity of nanoparticles with covalently attached organic monolayers. Nanotoxicology 3: 339-347.
44. Tatur S, Maccarini M, Barker R, Nelson A, Fragneto G. 2013. Effect of functionalized gold nanoparticles on floating lipid bilayers. Langmuir 29: 6606-6614.
45. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35: 206-221.
46. Vasir JK, Labhasetwar V. 2007. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 8: 718-728.
47. Verma A, Uzun O, Hu Y, Hu Y, Han HS, Watson N, Chen S, Irvine DJ, Stellacci F. 2008. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 7: 588-595.
48. Witte I, Plappert U, de Wall H, Hartmann A. 2007. Genetic toxicity assessment: employing the best science for human safety evaluation part III: the comet assay as an alternative to in vitro clastogenicity test for early drug candidate selection. Toxicol. Sci. 97: 21-26.
49. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T. 2006. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6: 1794-1807.
50. Xia T, Kovochich M, Liong M, Zink JI, Nel AE. 2008. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano 2: 85-96.
51. Yah CS, Simate GS, Lyuke SE. 2012. Nanoparticles toxicity and their routes of exposures. Pak. J. Pharm. Sci. 25: 477-491.
52. Yang H, Liu C, Yang D, Zhang H, Xi Z. 2009. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J. Appl. Toxicol. 29: 69-78.